CA3105726A1 - Anticorps anti-bcl-2 et dosage immunologique pour le diagnostic du cancer - Google Patents
Anticorps anti-bcl-2 et dosage immunologique pour le diagnostic du cancer Download PDFInfo
- Publication number
- CA3105726A1 CA3105726A1 CA3105726A CA3105726A CA3105726A1 CA 3105726 A1 CA3105726 A1 CA 3105726A1 CA 3105726 A CA3105726 A CA 3105726A CA 3105726 A CA3105726 A CA 3105726A CA 3105726 A1 CA3105726 A1 CA 3105726A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- seq
- label
- homology
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title claims abstract description 35
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 15
- 201000011510 cancer Diseases 0.000 title claims abstract description 15
- 238000003018 immunoassay Methods 0.000 title claims abstract description 11
- 238000003745 diagnosis Methods 0.000 title description 2
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 29
- 238000002965 ELISA Methods 0.000 claims abstract description 11
- 239000000523 sample Substances 0.000 claims description 56
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 238000003556 assay Methods 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 229960002685 biotin Drugs 0.000 claims description 28
- 239000011616 biotin Substances 0.000 claims description 28
- 235000020958 biotin Nutrition 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 210000002700 urine Anatomy 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims description 7
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims description 7
- 239000005515 coenzyme Substances 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 238000013096 assay test Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108091006629 SLC13A2 Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 241000251730 Chondrichthyes Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 150000001615 biotins Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000051711 human BCL2 Human genes 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241001416183 Ginglymostomatidae Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101100381517 Mus musculus Bcl2 gene Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000415294 Orectolobidae Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- GCSNAXXOAPCMDD-UHFFFAOYSA-N CC=1C=C(C=C(C1N)C)C1=CC(=C(N)C(=C1)C)C.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C Chemical compound CC=1C=C(C=C(C1N)C)C1=CC(=C(N)C(=C1)C)C.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C GCSNAXXOAPCMDD-UHFFFAOYSA-N 0.000 description 1
- 101100086716 Caenorhabditis elegans ran-3 gene Proteins 0.000 description 1
- 101100080643 Caenorhabditis elegans ran-4 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 101100480530 Danio rerio tal1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- RCZNYTXJVULKCR-UHFFFAOYSA-N I.I.I.I.I.I.I.I Chemical compound I.I.I.I.I.I.I.I RCZNYTXJVULKCR-UHFFFAOYSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 101100480538 Mus musculus Tal1 gene Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 101100312945 Pasteurella multocida (strain Pm70) talA gene Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DWQOTEPNRWVUDA-UHFFFAOYSA-N chembl1442125 Chemical compound OC(=O)C1=CC=CC=C1N=NC1=CC=C(O)C=C1 DWQOTEPNRWVUDA-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- BABWHSBPEIVBBZ-UHFFFAOYSA-N diazete Chemical compound C1=CN=N1 BABWHSBPEIVBBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne un anticorps monoclonal qui reconnaît le BCL-2 humain sous sa forme native. L'invention concerne également une lignée cellulaire d'hybridome qui produit l'anticorps monoclonal, et des dosages immunologiques tels que ELISA et des tests de dosage à écoulement latéral pour quantifier la quantité de BCL-2 pour diagnostiquer un cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694142P | 2018-07-05 | 2018-07-05 | |
| US62/694,142 | 2018-07-05 | ||
| PCT/US2019/040683 WO2020010304A2 (fr) | 2018-07-05 | 2019-07-05 | Anticorps anti-bcl-2 et dosage immunologique pour le diagnostic du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3105726A1 true CA3105726A1 (fr) | 2020-01-09 |
Family
ID=69059971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3105726A Pending CA3105726A1 (fr) | 2018-07-05 | 2019-07-05 | Anticorps anti-bcl-2 et dosage immunologique pour le diagnostic du cancer |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3817756A4 (fr) |
| JP (1) | JP2021530247A (fr) |
| CA (1) | CA3105726A1 (fr) |
| WO (1) | WO2020010304A2 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001057060A1 (fr) * | 2000-02-01 | 2001-08-09 | Human Genome Sciences, Inc. | Polynucleotides semblables a bcl-2, polypeptides et anticorps |
| US8034549B2 (en) * | 2006-02-09 | 2011-10-11 | University Of South Florida | Detection of cancer by elevated levels of BCL-2 |
| BR112016000231A8 (pt) * | 2013-07-12 | 2019-12-31 | Genentech Inc | métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos |
-
2019
- 2019-07-05 EP EP19830072.5A patent/EP3817756A4/fr active Pending
- 2019-07-05 CA CA3105726A patent/CA3105726A1/fr active Pending
- 2019-07-05 JP JP2021521944A patent/JP2021530247A/ja active Pending
- 2019-07-05 WO PCT/US2019/040683 patent/WO2020010304A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021530247A (ja) | 2021-11-11 |
| EP3817756A2 (fr) | 2021-05-12 |
| WO2020010304A3 (fr) | 2020-03-12 |
| EP3817756A4 (fr) | 2022-03-30 |
| WO2020010304A2 (fr) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5941615B2 (ja) | ヒトｃｘｃｌ１タンパク質の免疫学的測定方法 | |
| US11372001B2 (en) | Anti-human IgG4 monoclonal antibody and methods of making and using same | |
| JP6324970B2 (ja) | 抗ウロプラキンｉｉ抗体システムおよび方法 | |
| AU2015207665B2 (en) | Cell surface prostate cancer antigen for diagnosis | |
| EP3027652A1 (fr) | Anticorps anti-pla2r et utilisations associées | |
| WO2015050107A1 (fr) | Procédé de détection d'une tumeur pancréatique, anticorps, et kit de détection de tumeur pancréatique | |
| JP2016500659A5 (fr) | ||
| JP7200375B2 (ja) | ヒト抗ミュラー管ホルモンに対する特異抗体およびその使用 | |
| RU2019110953A (ru) | Моноклональное антитело, специфически связывающееся с тиоредоксином-1, и его применение | |
| US20050214301A1 (en) | Antibodies specific for BCR-ABL fusion protein and uses thereof | |
| US20210395394A1 (en) | Antibody against pan-species-specific plasmodium lactate dehydrogenase | |
| KR20210049894A (ko) | 항-인간 심근 트로포닌 i 재조합 항체 | |
| CA3105726A1 (fr) | Anticorps anti-bcl-2 et dosage immunologique pour le diagnostic du cancer | |
| WO2016194363A1 (fr) | Anticorps monoclonal vap-1 anti-humain | |
| US10073099B2 (en) | Methods and diagnostics for cancer detection and treatment monitoring | |
| US9127054B2 (en) | Immunoassay of cofilin 1 protein | |
| WO2022080305A1 (fr) | Anticorps anti-ptdss2 | |
| CN108727493B (zh) | 抗Stathmin单克隆抗体及其用途 | |
| KR20210067120A (ko) | Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도 | |
| RU2022106115A (ru) | Эпитоп тиоредоксина-1 и моноклональное антитело, специфично связывающееся с ним | |
| RU2022106116A (ru) | Эпитоп тиоредоксина-1 и моноклональное антитело, специфично связывающееся с ним | |
| JP5585587B2 (ja) | ５．９ｋＤａペプチドの免疫学的測定方法 | |
| JP6183920B2 (ja) | 腎炎の病変部位の検査方法およびそのための試薬 | |
| CN116234823A (zh) | 用于在免疫组织化学（ihc）方案中诊断癌症的抗体 | |
| JP2003180345A (ja) | 遊離型肝細胞増殖因子受容体の測定方法 |